We are live on ! Find out more
OrbiMed

OrbiMed Portfolio holdings

AUM $5.5B Turnover 43.13%
1-Year Est. Return 92.2%
 

OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.

This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+92.2%
3 Year Est. Return
+415.45%
5 Year Est. Return
+495.5%
10 Year Est. Return
+2,794.97%
AUM
$9.6B
AUM Growth
+$79.4M
Cap. Flow
-$357M
Cap. Flow %
-3.72%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21
Avg Time Held Equity + Options
1.5 years
Top 10 Avg Time Held Equity + Options
1.8 years
Top 20 Avg Time Held Equity + Options
1.5 years
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
1.8 years
Top 20 Avg Time Held Equity only
1.5 years

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Miscellaneous 5.91%
3 Financials 0.34%
4 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
MDVN
26
DELISTED
Medivation
MDVN
$121M 1.26%
2,001,400
+1,500,400
+299% +$85.1M
2015 Q4
2 quarters
ILMN icon
27
Illumina
ILMN
$30.6B
$119M 1.24%
869,894
-55,306
-6% -$7.86M
2013 Q2
12 quarters
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$11.3B
$118M 1.23%
1,518,500
+495,300
+48% +$42.1M
2015 Q2
4 quarters
LLY icon
29
Eli Lilly
LLY
$1.26T
$116M 1.21%
1,476,800
-1,064,500
-42% -$80.1M
2015 Q3
3 quarters
COO icon
30
Cooper Companies
COO
$11.5B
$116M 1.21%
2,705,200
-478,400
-15% -$19.1M
2014 Q3
7 quarters
WMGI
31
DELISTED
Wright Medical Group
WMGI
$114M 1.19%
6,545,163
-1,799,947
-22% -$33M
2014 Q3
7 quarters
MRK icon
32
Merck
MRK
$353B
$110M 1.15%
2,007,444
+1,786,945
+810% +$95.1M
2016 Q1
1 quarter
ISEE
33
DELISTED
IVERIC bio
ISEE
$110M 1.14%
2,148,100
+53,600
+3% +$2.66M
2014 Q3
7 quarters
ZBH icon
34
Zimmer Biomet
ZBH
$19.3B
$104M 1.08%
888,375
+782,285
+737% +$88.5M
2013 Q2
12 quarters
JNJ icon
35
Johnson & Johnson
JNJ
$671B
$94.3M 0.98%
777,600
+245,800
+46% +$27.9M
2013 Q2
12 quarters
MOH icon
36
Molina Healthcare
MOH
$11.5B
$91.7M 0.96%
+1,838,000
New +$98.2M
2016 Q2
0 quarters
ACHN
37
DELISTED
Achillion Pharmaceuticals
ACHN
$91.1M 0.95%
11,681,600
+161,900
+1% +$1.39M
2015 Q3
3 quarters
PBYI icon
38
Puma Biotechnology
PBYI
$369M
$88.3M 0.92%
2,964,025
+210,600
+8% +$6.58M
2014 Q2
8 quarters
AGN.PRA
39
DELISTED
Allergan plc
AGN.PRA
– –
-104,200
Closed -$87M –
GKOS icon
40
Glaukos
GKOS
$14.4B
$84.5M 0.88%
2,897,938
– –
2015 Q2
4 quarters
NBIX icon
41
Neurocrine Biosciences
NBIX
$16.8B
$82.5M 0.86%
1,815,474
-838,400
-32% -$38.6M
2013 Q2
12 quarters
MNK
42
DELISTED
Mallinckrodt
MNK
$79.6M 0.83%
1,309,000
– –
2014 Q3
7 quarters
CRVS icon
43
Corvus Pharmaceuticals
CRVS
$858M
$76.7M 0.8%
5,379,349
+120,899
+2% +$1.63M
2016 Q1
1 quarter
SHPG
44
DELISTED
Shire
SHPG
$72.5M 0.76%
394,009
+93,638
+31% +$16.9M
2013 Q3
11 quarters
MGLN
45
DELISTED
Magellan Health Services
MGLN
$71.7M 0.75%
1,090,600
-818,400
-43% -$55.1M
2014 Q3
7 quarters
HUM icon
46
Humana
HUM
$53.2B
$61.1M 0.64%
339,700
– –
2016 Q1
1 quarter
INSY
47
DELISTED
Insys Therapeutics
INSY
$60.7M 0.63%
4,688,240
+130,500
+3% +$1.9M
2014 Q3
7 quarters
MDT icon
48
Medtronic
MDT
$131B
$57.8M 0.6%
666,299
– –
2015 Q2
4 quarters
NTLA icon
49
Intellia Therapeutics
NTLA
$1.37B
$56.8M 0.59%
+2,662,180
New +$70.8M
2016 Q2
0 quarters
BLUE icon
50
DELISTED
bluebird bio
BLUE
$51.3M 0.54%
91,544
+18,551
+25% +$10.5M
2015 Q1
5 quarters

Similar funds

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.6B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed withdrew a net $357M in Q2 2016, closing 21 positions and reducing 32 holdings. Its most notable exit was Allergan plc, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in Molina Healthcare worth $91.7M.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.6B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.6B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.